Ipramid

Simvastatin, the active ingredient in Ipramid, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adult patients, helping to lower LDL‑cholesterol and reduce cardiovascular risk.

GNH USA supplies Ipramid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Simvastatin works within the lipid‑lowering therapeutic class to manage disorders of cholesterol metabolism. - Hypercholesterolemia: reduces elevated LDL‑cholesterol levels. - Primary hyperlipidemia: lowers total cholesterol and triglycerides. - Mixed dyslipidemia: improves overall lipid profile by decreasing LDL and increasing HDL. - Prevention of cardiovascular disease: diminishes the risk of heart attacks and strokes in at‑risk patients.

Simvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate discomfort. - Muscle pain (myalgia): aching or soreness in muscles. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of queasiness. - Constipation: infrequent bowel movements. - Elevated liver enzymes: mild increase in hepatic function tests.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Allergic reactions: rash, itching, or swelling. - Myopathy: significant muscle weakness. - Acute renal failure: sudden loss of kidney function. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating Simvastatin therapy, consider the following precautions. - Monitor liver function: obtain baseline and periodic hepatic enzyme tests. - Assess muscle symptoms: discontinue if severe myopathy or rhabdomyolysis occurs. - Avoid in pregnancy: contraindicated due to fetal toxicity. - Use caution in elderly: increased susceptibility to adverse effects. - Review concomitant medications: especially strong CYP3A4 inhibitors. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Simvastatin interacts with several drugs that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may cause dangerous accumulation. - Gemfibrozil: significantly raises risk of myopathy. - High‑dose niacin: enhances muscle toxicity. - Cyclosporine: increases Simvastatin levels. - Danazol: elevates risk of hepatic and muscle adverse events.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly increase Simvastatin concentrations. - Beta‑blockers: monitor for additive cardiovascular effects. - Anticoagulants (warfarin): watch INR for potential changes. - Digoxin: observe for altered drug levels. - Grapefruit juice: can raise Simvastatin exposure.